Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1999 1
2008 2
2009 2
2012 1
2013 2
2014 1
2015 2
2016 3
2017 2
2019 2
2020 4
2021 4
2022 4
Text availability
Article attribute
Article type
Publication date

Search Results

27 results
Results by year
Filters applied: . Clear all
Page 1
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC).
Cohen EEW, Bell RB, Bifulco CB, Burtness B, Gillison ML, Harrington KJ, Le QT, Lee NY, Leidner R, Lewis RL, Licitra L, Mehanna H, Mell LK, Raben A, Sikora AG, Uppaluri R, Whitworth F, Zandberg DP, Ferris RL. Cohen EEW, et al. Among authors: bifulco cb. J Immunother Cancer. 2019 Jul 15;7(1):184. doi: 10.1186/s40425-019-0662-5. J Immunother Cancer. 2019. PMID: 31307547 Free PMC article. Clinical Trial.
The Society for Immunotherapy of Cancer statement on best practices for multiplex immunohistochemistry (IHC) and immunofluorescence (IF) staining and validation.
Taube JM, Akturk G, Angelo M, Engle EL, Gnjatic S, Greenbaum S, Greenwald NF, Hedvat CV, Hollmann TJ, Juco J, Parra ER, Rebelatto MC, Rimm DL, Rodriguez-Canales J, Schalper KA, Stack EC, Ferreira CS, Korski K, Lako A, Rodig SJ, Schenck E, Steele KE, Surace MJ, Tetzlaff MT, von Loga K, Wistuba II, Bifulco CB; Society for Immunotherapy of Cancer (SITC) Pathology Task Force.. Taube JM, et al. Among authors: bifulco cb. J Immunother Cancer. 2020 May;8(1):e000155. doi: 10.1136/jitc-2019-000155. J Immunother Cancer. 2020. PMID: 32414858 Free PMC article.
Neoadjuvant anti-OX40 (MEDI6469) therapy in patients with head and neck squamous cell carcinoma activates and expands antigen-specific tumor-infiltrating T cells.
Duhen R, Ballesteros-Merino C, Frye AK, Tran E, Rajamanickam V, Chang SC, Koguchi Y, Bifulco CB, Bernard B, Leidner RS, Curti BD, Fox BA, Urba WJ, Bell RB, Weinberg AD. Duhen R, et al. Among authors: bifulco cb. Nat Commun. 2021 Feb 16;12(1):1047. doi: 10.1038/s41467-021-21383-1. Nat Commun. 2021. PMID: 33594075 Free PMC article. Clinical Trial.
Cancer microenvironment and genomics: evolution in process.
Leong SP, Witz IP, Sagi-Assif O, Izraely S, Sleeman J, Piening B, Fox BA, Bifulco CB, Martini R, Newman L, Davis M, Sanders LM, Haussler D, Vaske OM, Witte M. Leong SP, et al. Among authors: bifulco cb. Clin Exp Metastasis. 2022 Feb;39(1):85-99. doi: 10.1007/s10585-021-10097-9. Epub 2021 May 10. Clin Exp Metastasis. 2022. PMID: 33970362 Review.
Cumulative suppressive index as a predictor of relapse free survival and overall survival in Human Papilloma Virus-negative oral squamous cell carcinomas with negative resection margins.
Hum L, Bethmann D, Feng Z, Chang SC, Eckert A, Ballesteros-Merino C, Keschke C, Kappler M, Bifulco CB, Wickenhauser C, Seliger B, Fox BA, Bryan Bell R. Hum L, et al. Among authors: bifulco cb. Head Neck. 2021 Feb;43(2):568-576. doi: 10.1002/hed.26520. Epub 2020 Oct 23. Head Neck. 2021. PMID: 33094869
Intratumoral Plasmid IL12 Expands CD8+ T Cells and Induces a CXCR3 Gene Signature in Triple-negative Breast Tumors that Sensitizes Patients to Anti-PD-1 Therapy.
Telli ML, Nagata H, Wapnir I, Acharya CR, Zablotsky K, Fox BA, Bifulco CB, Jensen SM, Ballesteros-Merino C, Le MH, Pierce RH, Browning E, Hermiz R, Svenson L, Bannavong D, Jaffe K, Sell J, Foerter KM, Canton DA, Twitty CG, Osada T, Lyerly HK, Crosby EJ. Telli ML, et al. Among authors: bifulco cb. Clin Cancer Res. 2021 May 1;27(9):2481-2493. doi: 10.1158/1078-0432.CCR-20-3944. Epub 2021 Feb 16. Clin Cancer Res. 2021. PMID: 33593880 Free PMC article. Clinical Trial.
27 results